Guangdong Biolight Meditech Co (300246) Fair Value & Analysis
Healthcare · CN · Market cap 4.7B CNY
Analysis
Guangdong Biolight Meditech Co (300246) currently trades at ¥17.87, while our model-based Fair Value estimate is ¥19.35 — implying the stock looks roughly 8.3% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Guangdong Biolight Meditech Co., Ltd. engages in the research and development, production, sale, and service of medical devices products and solutions in China. It operates in two segments, Life Information and Support, and Kidney Disease. The company offers emergency and critical care monitor, subcritical care monitor, general ward monitor, outpatient monitor, neonatal monitor, infusion pump, electrocardiograph, maternal and fetal monitor, defibrillator, multifunctional suspension device, internet of things, and central station; hemodiafiltration equipment, peritoneal dialysis equipment, liquid supply system, and hemodialysis water equipment; and finger clip oximeter, sphygmomanometer, fetal heart rate monitor, body temperature monitoring system, and home medical mall, as well as hemoperfusion devices, high throughput and low flu hemodialyzer, hemodialysis concentrate, dry powder, citric acid disinfectant, tube/puncture needle, dialysate filter, and dialysis fluid filter. It offers…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.